Please enable JS

ARTICLES & PRESS RELEASES

FILTER BY TYPE

Most Recent

Categories

ARCHIVES

Seth’s 50 State Network Advocate Talking Points: Prior Authorization

Jun 09/GHLF Staff / Seth's 50 State Network Talking Points

1.      When a patient has to wait an extended period of time before beginning treatment, the patient, physician and public health suffers. 2.      The current system of prior authorization burdens the patient and physician leading to: a.       Delayed treatment and prolonged illness b.      Unstabilized care and the potential for permanent damage to occur c.       Diminished […]

READ MORE

Seth’s 50 State Network Advocate Brief: Prior Authorization

Jun 09/GHLF Staff / Memos Seth's 50 State Network

  How Can You Help?   Many states are currently introducing or revising legislation regarding prior authorization. Through your grassroots advocacy as part of the 50 State Network— online and in-person — the Prior Authorization message of poor outcomes, inefficiencies, and higher costs can be conveyed to:   State elected officials and staffers (legislators and […]

READ MORE

50 State Network Advocate Talking Points: Non-Preferred and Specialty Tier Drugs

Jun 09/GHLF Staff / Seth's 50 State Network Talking Points

1. As patients, our core concerns are to safeguard safety and the physician-patient relationship. 2. We believe only physicians should decide if a non-preferred or specialty tier drug is right for their patients. 3. Patients should pay the same for non-preferred drugs as they do for preferred drugs when it is the best or only […]

READ MORE

50 State Network Advocate Brief: Non-Preferred and Specialty Tier Drugs

Jun 09/GHLF Staff / Memos Seth's 50 State Network

How can you help? Help support bills that limit patients’ costs for specialty tier drugs. 87% of stand-alone Medicare Part D Prescription Drug Plans and 98% of Medicare Advantage-Prescription Drug Plans use specialty tiers, and this can be very expensive for those in need of special medicines. Patients who need non-preferred or specialty tier drugs […]

READ MORE